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Abstract
ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor, crizotinib. We investigated the
usefulness of ROS1 immunohistochemistry (IHC) for the detection of patients who harbor ROS1 rearrangements in two
separate cohorts. We also compared ROS1 IHC with ALK IHC in terms of diagnostic performance to predict each gene
rearrangement. In a retrospective cohort, IHC was performed in 219 cases of lung adenocarcinoma with already known
genetic alterations. In a prospective cohort, we performed IHC for 111 consecutive cases of lung adenocarcinoma and
confirmed the results by subsequent FISH. In the retrospective cohort, all 8 ROS1-rearranged tumors were immunoreactive,
and 14 of 211 ROS1-wild cases were immunoreactive (sensitivity 100% and specificity 93.4%). In the prospective cohort, all
IHC-negative cases were FISH-negative, and 5 of 34 ROS1 immunoreactive cases were ROS1-rearranged (sensitivity 100%
and specificity 72.6%). In ROS1-wild tumors, ROS1 protein was more expressed in the tumors of ever-smokers than in those
of never-smokers (p = 0.003). ALK IHC showed 100% sensitivity and 98.1 to 100% specificity in both patient cohorts. In
conclusion, ROS1 IHC is highly sensitive, but less specific compared with ALK IHC for detection of the corresponding
rearrangement. ROS1 IHC-reactive tumors, especially when the tumor is stained with moderate to strong intensity or a
diffuse pattern, are recommended to undergo FISH to confirm the gene rearrangement.
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Introduction
Targeted therapies based on molecular diagnostics have opened
a new era of personalized medicine in lung cancer treatment [1,2].
The EGFR mutation and ALK rearrangement are currently the
most important predictive factors for a response to EGFR tyrosine
kinase inhibitors (gefitinib, erlotinib, or afatinib) and the ALK
inhibitor (crizotinib), respectively [2]. New predictive biomarkers,
such as the ROS1 rearrangement, RET rearrangement, BRAF
mutation, and HER2 mutation, have emerged in anticipation of
personalized therapy based on molecular diagnostics and targeted
therapy [3]. Among these, ROS1 and ALK gene fusions are
unique in that they are derived from a chromosomal rearrange-
ment, the tyrosine kinase domains are similar to each other, and
they are strongly predictive of response to an ALK inhibitor, such
as crizotinib [4]. Thus, it is clinically important to detect patients
who will benefit from such inhibitor treatment. However, these
rearrangements are rare, comprising 2–5% of all non-small cell
carcinomas [5–7]. Thus, an effective screening test is essential.
Currently, fluorescence in situ hybridization (FISH) is the gold
standard method to detect patients harboring the ALK rearrange-
ment, and has been used as a confirmatory test in the
clinicopathologic studies for ROS1 [6,8]. However, FISH has
several limitations such as high cost, time-consuming, and
requiring an expert’s reading. In contrast, immunohistochemistry
(IHC) is less time consuming, is cost-effective, can be performed on
small biopsies, and theoretically, can identify all fusion variants
[9,10].
The role of ALK IHC has been extensively studied [11–15].
However, there are a few studies on ROS1 IHC [16–19], and
there have not been any studies on the combined ROS1 and ALK
rearrangements, and comprehensive results on both ROS1 and
ALK IHC have not been reported to date.
In this study, we investigated the usefulness of ROS1 IHC for
the detection of patients who harbor ROS1 rearrangements in two
separate cohorts. We also compared ROS1 IHC with ALK IHC
in terms of diagnostic performance to predict each gene
rearrangement.
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Materials and Methods
Study populations
The study populations were composed of two patient cohorts
with histologically confirmed lung adenocarcinoma. The retro-
spective cohort comprised 219 cases, in which genetic analyses
(EGFR mutation, KRAS mutation, ALK rearrangement, and
ROS1 rearrangement) were already performed. This cohort was
enriched for tumors from never smokers (178 out of 219; 81.3%).
Specimens tested in this cohort were from January 2005 to
January 2012 and consisted of 103 small biopsy samples (66 from
lung, 6 pleura, 22 lymph node, and 9 soft tissue) and 116 large
Table 1. Clinicopathologic Characteristics of Patients
Factors Retrospective Cohort (n=219) Prospective Cohort (n =111)
Mean age (range) 59.2 (28–86) 63.9 (32–84)
Sex Male 68 (31.1) 68 (61.3)
Female 151 (68.9) 43 (38.7)
Smoking status Never 178 (81.3) 55 (49.5)
Former 17 (7.8) 33 (29.7)
Current 24 (11.0) 23 (20.7)
Stage I 38 (17.4) 22 (19.8)
II 23 (10.5) 9 (8.1)
III 60 (27.4) 19 (17.1)
IV 98 (44.7) 61 (55.0)
Mutation status EGFR 68 (31.1) 31 (27.9)
KRAS 10 (4.6) 9 (8.1)
ROS1 8 (3.7) 5 (4.5)
ALK 12 (5.5) 8 (7.2)
Pan-negative 121 (55.3) 29 (26.1)
Not available 0 (0.0) 29 (26.1)
doi:10.1371/journal.pone.0103333.t001
Figure 1. Immunohistochemical findings of ROS1-rearranged tumors. An ROS1-rearrangned tumor showed strong and diffuse cytoplasmic
staining (a) (inset: ROS1 FISH with split signals). Other tumors showed cytoplasmic staining with membrane accentuation (b), membranous staining
with weaker cytoplasmic intensity (c), or cytoplasmic or paranuclear aggregates (d).
doi:10.1371/journal.pone.0103333.g001
ROS1 Immunohistochemistry in Lung Adenocarcinoma
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samples including open resection and excisional biopsy (102 from
lung, 1 pleura, 9 lymph node, and 4 brain). The prospective cohort
comprised 111 cases that were prospectively examined for the
expression of ROS1 and ALK by IHC and confirmed by FISH.
Mutation analysis for the EGFR and KRAS genes was also
performed in 82 patients (73.9%) of the prospective cohort.
Specimens tested in this cohort were from February 2013 to May
2013 and consisted of 64 small biopsy samples (44 from lung, 3
pleura, 14 lymph node, and 3 soft tissue) and 47 large samples
including open resection and excisional biopsy (42 from lung, 4
lymph node, and 1 brain). This study was approved by the
Institutional Review Board of Severance Hospital. All patients
provided written informed consent for the genetic analysis.
Histologic review
Samples were classified according to the 2011 International
Association for the Study of Lung Cancer/American Thoracic
Society/European Respiratory Society guidelines [20]. When
Figure 2. Immunohistochemical findings of ROS1-non-rearranged tumors.Most ROS1-non-rearranged tumors showed no immunoreactivity,
or focal and patchy staining with weak intensity (a, b) (inset: ROS1 FISH without split signals). One tumor showed strong and diffuse staining pattern,
which is similar to that of rearranged tumors (c). ROS1 is occasionally expressed in surrounding type II pneumocytes (d).
doi:10.1371/journal.pone.0103333.g002
Figure 3. Representative photos from ALK IHC. An ALK-rearranged tumor shows strong and diffuse staining (a) (inset: ALK FISH with split
signals). In contrast, an ALK-non-rearranged tumor shows weak and patchy staining (b) (inset: ALK FISH without split signals).
doi:10.1371/journal.pone.0103333.g003
ROS1 Immunohistochemistry in Lung Adenocarcinoma
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poorly differentiated tumors were encountered, immunohisto-
chemistry for TTF-1, napsin A, and p63 (or p40) was performed to
differentiate adenocarcinoma from squamous cell carcinoma [21].
EGFR and KRAS mutation analysis
To determine the EGFR and KRAS mutation status, DNA was
extracted using a DNeasy isolation kit (Qiagen, Valencia, CA,
USA) from formalin-fixed paraffin-embedded tissues according to
the manufacturer’s instructions. For the EGFR gene, direct DNA
sequencing of exons 18 through 21 was performed in the
retrospective cohort, and the peptide nucleic acid clamping
method was performed in the prospective cohort [22]. For the
KRAS gene, direct DNA sequencing of codons 12 and 13 was
performed. Each case was classified as positive or negative for a
mutation based on comparison with the wild-type sequence.
Fluorescence in situ hybridization
To identify ROS1 and ALK rearrangements, fluorescent in situ
hybridization (FISH) was performed on the whole section of
formalin-fixed, paraffin-embedded (FFPE) tumors using a break-
apart ROS1 or ALK probe (Vysis LSI Dual Color, Break Apart
Rearrangement Probe; Abbott Molecular, Abbot Park, IL, USA),
respectively. ROS1 or ALK rearrangements were scored as
positive when .15% of tumor cells displayed split signals or
isolated signals containing a kinase domain (green for ROS1 and
red for ALK), as previously described [6,23].
Immunohistochemistry and interpretation
FFPE tissues were sectioned at a thickness of 4 mm and stained
using the Ventana automated immunostainer BenchMark XT
(Ventana Medical Systems, Tucson, AZ, USA). The slides were
dried at 60uC for 1 hour and deparaffinized using EZ Prep
(Ventana Medical Systems) at 75uC for 4 minutes. Cell
conditioning was performed using CC1 solution (Ventana Medical
Systems) at 100uC for 64 minutes. ROS1 (rabbit monoclonal,
clone D4D6, Cell Signaling Technology, Danvers, MA, USA) and
ALK (rabbit monoclonal, clone D5F3, Cell Signaling Technology,
Danvers, MA, USA) antibodies were diluted to 1:50, treated, and
incubated at 37uC for 32 minutes. Signals were detected using the
OptiView DAB IHC Detection Kit (Ventana Medical Systems).
Counterstaining was performed with Hematoxylin I (Ventana
Medical Systems) for 4 minutes at room temperature. IHC-
Figure 4. Comparison of the H-score and extent of ROS1 (a, b) and ALK (c, d) immunoreactivity in gene-rearranged vs. non-
rearranged tumors. Scatter dot plots for H-scores (a, c) and percentage of immunoreactive cells (b, d) show significantly increased expression of
each protein in rearranged tumors (p,0.001). All rearranged tumors show an H-score of more than 100 and extent of more than 75%.
doi:10.1371/journal.pone.0103333.g004
ROS1 Immunohistochemistry in Lung Adenocarcinoma
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positive controls included gene rearranged lung tumor confirmed
by FISH. Negative controls included non-rearranged lung tumor
confirmed by FISH as well as normal lung tissue.
The stained slides were reviewed by three pathologists (Y.J.C.,
J.S.L., and H.S.S.) blinded to FISH results. To analyze the IHC
results in detail, the stained slides were scored by the H-score
Table 2. Diagnostic performance of IHC to predict gene rearrangement according to cutoff in both patient cohorts
ROS1 ALK
Cutoff Sensitivity Specificity Sensitivity Specificity
H-score .0 100% 86.4% 100% 99.4%
$50 100% 94.3% 100% 99.7%
$100 100% 97.8% 100% 100%
$150 92.3% 98.4% 95.0% 100%
$200 84.6% 99.7% 75.0% 100%
$250 53.8% 100% 20.0% 100%
Extent $25% 100% 92.4% 100% 99.7%
$50% 100% 95.6% 100% 100%
$75% 100% 96.8% 100% 100%
Intensity $2+ 100% 95.0% 100% 99.4%
=3+ 84.6% 98.4% 75% 100%
doi:10.1371/journal.pone.0103333.t002
Figure 5. Comparison of the H-score in ROS1-non-rearranged tumors according to smoking history. The scatter dot plot shows that the
ROS1 protein is more expressed in tumors of smokers’ than in those of never-smokers (p = 0.003).
doi:10.1371/journal.pone.0103333.g005
ROS1 Immunohistochemistry in Lung Adenocarcinoma
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method, which is the sum of products of multiplying intensity (0, 1,
2, and 3) by extent of each staining intensity (%) [16]. H-scores
range from 0 to 300. The definition of intensity was as follows: 0
for no detectable staining, 1+ for weak reactivity mainly detectable
at high magnification (20–406 objective), and 2+ or 3+ for more
intense (moderate or strong, respectively) reactivity easily detect-
able at low magnification (46 objective) [16]. In cases with a
discrepancy in IHC scoring, all pathologists reviewed the cases in
conference and a consensus score was established.
Statistical analysis
Relationships between clinicopathologic parameters were eval-
uated using the chi-square test. Student’s t-test was used to
compare means between two groups. Differences were considered
significant for p,0.05. All statistical analyses were conducted
using SPSS v.17 (SPSS, Chicago, IL).
Results
FISH and IHC in the retrospective cohort
A total of 219 cases were evaluated for ROS1 and ALK
rearrangements using FISH and subsequent IHC. The clinico-
pathologic characteristics of the retrospective cohort are summa-
rized in Table 1.
In FISH analyses, 8 of 219 (3.7%) were ROS1-rearranged, and
12 of 219 (5.5%) tumors were ALK-rearranged by FISH. These
rearrangements were mutually exclusive.
In IHC analyses, all 8 ROS1-rearranged cases were ROS1-
immunoreactive, showing an H-score of more than 100, extent of
more than 75%, and the presence of 2+ or 3+ intensity (Figure 1).
Of the 211 ROS1-wild cases, 14 cases were also ROS1-
immunoreactive (Figure 2). However, most cases showed focal
and weak immunoreactivity (H-score mean: 46.4, range: 5–160).
All 12 ALK-rearranged tumors were ALK immunoreactive,
showing an H-score of more than 100, an extent of more than
75%, and the presence of 2+ or 3+ intensity (Figure 3a). In
contrast, all ALK-wild cases showed no immunoreactivity. Both
the H-score and extent were significantly different between ROS1-
or ALK-rearranged and wild groups (Figure 4, p,0.001). There
were no double-immunoreactive cases for both ROS1 and ALK
IHC. In 2 cases, the surrounding reactive type II pneumocytes
showed ROS1 immunoreactivity (Figure 2d).
IHC and FISH in the prospective cohort
A total of 111 cases with unknown genetic alterations were
screened using ROS1 and ALK IHC, and all cases were evaluated
for ROS1 and ALK rearrangements using FISH. The clinico-
pathologic characteristics of the prospective cohort are summa-
rized in Table 1. In IHC analyses, 34 of 111 (30.6%) were ROS1
immunoreactive, and 10 of 111 (9.0%) tumors were ALK
immunoreactive. In subsequent FISH analyses, 5 of 34 ROS1
immunoreactive tumors were ROS1-rearranged by FISH. The
IHC of all 5 ROS1-rearranged tumors showed an H-score of more
than 100, an extent of more than 75%, and the presence of 2+ or
3+ intensity (Figures 1 and 4). Twenty-nine IHC-reactive/FISH-
negative cases showed variable H-scores (mean: 58.8; range 10–
240), extent (mean: 40; range 10 to 100), and intensity (1+ to 3+)
(Figures 2 and 4). All ROS1 IHC-negative tumors were ROS1-
wild by FISH.
Regarding ALK, 8 of 10 immunoreactive tumors were ALK-
rearranged. The IHC of all 8 ALK-rearranged tumors showed an
H-score of more than 100, an extent of more than 75%, and the
presence of 2+ or 3+ intensity. Two cases that were IHC-reactive/
FISH-negative showed less than 50% extent and an H-score of less
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than 100 (Figure 3b). All ALK IHC-negative tumors were ALK-
wild by FISH. Both the H-score and extent were significantly
different between the ROS1- or ALK-rearranged and -wild groups
(Figure 4, p,0.001).
There were 2 double-immunoreactive cases for ROS1 and ALK
IHC. For the first case, the H-scores were 30 and 190 for ROS1
and ALK, respectively, and this case was ALK-rearranged by
FISH. The second case’s H-scores were 20 and 40 for ROS1 and
ALK, respectively, and was wild-type for both genes by FISH. As
in the retrospective cohort, the surrounding reactive type II
pneumocytes were ROS1-immunoreactive in 6 cases.
IHC criteria to predict gene rearrangements
In the retrospective cohort, any immunoreactivity for ROS1
showed 100% sensitivity and 93.4% specificity to predict a ROS1
rearrangement. When the criteria were defined as (1) H-score of
100 or more, or (2) extent of 75% or more, or (3) presence of 2+ or
3+ intensity, the specificities were (1) 99.1%, (2) 98.6%, or (3)
98.1%, respectively. All criteria maintained 100% sensitivity. In
the prospective cohort, these criteria showed 100% sensitivity, but
the specificities were (1) 95.3%, (2) 93.4%, or (3) 88.7%,
respectively. In both patient cohorts, these criteria showed 100%
sensitivity and 95 to 97.8% specificity (Table 2).
Regarding ALK in the retrospective cohort, any immunoreac-
tivity showed 100% sensitivity and 100% specificity to predict an
ALK rearrangement. In the prospective cohort, ALK IHC was
also highly sensitive and specific (sensitivity 100% and specificity
98.1%). When the criteria were defined as H-score of 100 or more,
or extent with 75% or more, the sensitivity and specificity were
100% in both patient cohorts (Table 2).
ROS1 or ALK expression in non-rearranged tumors from
both patient cohorts
ROS1 protein was expressed in 43 of 317 ROS1-non-
rearranged tumors (13.6%) (Figure 2). The staining was sometimes
diffuse or intense (mean of H-score: 54.8, range: 5–240) (Figure 2c).
ROS1 protein was more expressed in the tumors of ever-smokers
than in those of never-smokers (Figure 5, p = 0.003). In contrast,
ALK protein was expressed in only 2 cases of 310 ALK-non-
rearranged tumors (0.6%) (Figure 3b). The staining was focal and
weak (H-score: 40 and 50), and both tumors were from never-
smokers.
Clinical and pathologic characteristics in both patient
cohorts
Patients with ROS1 or ALK rearrangements were significantly
younger than those with wild-type genes, as previously known
(Table 3). Never-smokers occupied 69.2% and 75.0% of patients
with ROS1 and ALK rearrangements, respectively (Tables 3, and
Table S1 and S2). However, clinical factors did not perfectly
predict which patient’s tumor harbors gene rearrangements.
Regarding drivers of genetic alterations, the EGFR mutation,
KRAS mutation, ROS1 rearrangement, and ALK rearrangement
were mutually exclusive in both cohorts.
Figure 6. Proposed diagnostic algorithm using ROS1 and ALK IHC. When the tumor shows moderate to strong, or diffuse staining on IHC,
FISH is recommend to confirm gene rearrangements. *The criteria should be determined based on each institutional method. According to this
present study, subsequent FISH analysis is recommended for cases with an H-score $100, extent $75%, or the presence of intensity 2+ or 3+.
doi:10.1371/journal.pone.0103333.g006
ROS1 Immunohistochemistry in Lung Adenocarcinoma
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Four predominant histologic types except lepidic were observed
in gene-rearranged cases, although comprehensive analyses were
limited by presence of small biopsies (Table S1 and S2). ROS1-
rearranged tumors showed a solid-predominant pattern (7.7%),
cribriform with extracellular mucin (15.4%), and the presence of
signet ring cells (7.7%) (Table S1). ALK rearranged tumors also
showed a solid-predominant pattern (50%), cribriform with
extracellular mucin (25%), and the presence of signet ring cells
(45%) (Table S2). However, these incidences were more frequent
than those of ROS1-rearranged tumors.
Discussion
In the present study, we demonstrated that IHC is an effective
screening tool for the detection of ROS1 rearrangements in lung
adenocarcinomas. We also showed that IHC is a sensitive tool, but
that non-rearranged tumors can be immunoreactive, so confir-
matory FISH is necessary, especially in ROS1-expressed tumors.
The ALK rearrangements have been the focus of intense
research over the last several years [2,5,8,9,11–15,23,24]. Specif-
ically, there have been many studies showing that IHC is a good
prescreening method for the detection of patients with ALK
rearrangement [9,11–15,25]. IHC is cost-effective and available in
most pathology laboratories. In addition, because most lung
cancer patients present with advanced-stage disease at the time of
diagnosis, the diagnosis of lung cancer is often based on only a
small biopsy. IHC can be performed on a few cancer cells. To use
IHC as a screening test in molecular-based targeted therapy, its
validation is necessary including correlation with the results of
other molecular methods. In our study, all FISH-positive cases
were immunoreactive, which was consistent with most previous
reports. Studies concerning ROS1 IHC also have been reported
recently [16,17,19]. ROS1 IHC showed 100% sensitivity for the
detection of ROS1 rearrangements in our study.
However, the specificity was different. While ALK IHC showed
99.4% specificity in all patient cohorts, ROS1 IHC showed 86.4%
specificity. Remarkably, specificity was the lowest in the prospec-
Figure 7. Heterogeneity of histology and immunohistochemical staining. One area of a ROS1-rearranged tumor shows a solid area with
intense immunostaining for ROS1 (a and c). Another area shows a predominantly signet ring cell feature with weaker immunostaining (b and d). Both
areas were ALK IHC-negative (e and f).
doi:10.1371/journal.pone.0103333.g007
ROS1 Immunohistochemistry in Lung Adenocarcinoma
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tive cohort (72.6%). This indicated that the expression of ALK is
very rare in ALK-non-rearranged tumors, but ROS1 is occasion-
ally expressed in ROS1-non-rearranged tumors. Interestingly,
when confined to cases with ROS1-wild alone, ROS1 was more
expressed in smokers’ tumors (Figure 5). This result was also
consistent with the notion that ROS1 immunoreactivity was more
prevalent in the prospective cohort, of which ever-smokers
comprised 50.5% (compared with 18.7% in the retrospective
cohort). Further studies are necessary to elucidate whether ROS1
is also implicated in tumor progression of some ROS1-non-
rearranged tumors and whether its expression could be affected by
smoking.
This present study also confirmed that, although ROS1 or ALK
proteins can be expressed in non-rearranged tumors, most cases
showed focal extent or a weak intensity pattern. Thus, we could
determine the IHC cutoff to predict gene rearrangement more
specifically (Table 2). In our study, all FISH-positive cases showed
an H-score of 100 or more, extent of 75% or more, or the presence
of 2+ or 3+ intensity on IHC. These cutoff lines showed 95 to
100% specificity in both patient cohorts, maintaining 100%
sensitivity. Thus, we propose the diagnostic algorithm shown in
Figure 6. Because gene rearrangements are rare, sensitive IHC
screening is reasonable before FISH. In addition, a proper cutoff
can enrich FISH-positive cases.
Our study indicated that a small biopsy sample from patients
with advanced stage can be enough and representative for IHC
screening. We tested it through the prospective cohort. All FISH-
positive cases showed diffuse staining pattern including biopsy
samples. For rearranged tumors, heterogeneous staining pattern,
that is definitive positive in one area and definitive negative in
other area, was very rare.
As shown in previous studies, ROS1 or ALK IHC showed a
predominantly cytoplasmic staining pattern. However, some cases
showed a membrane-accentuated pattern, or a cytoplasmic or
paranuclear aggregated pattern, especially in ROS1-rearranged
tumors (Figure 2). These patterns were reported to be associated
with molecular variants [16,18]. Most rearranged tumors showed
an intense staining pattern, but in the signet ring cell areas, the
expression was weaker (Figure 7), as noted in previous reports
[11,16].
Our study also suggested that ROS1- or ALK-rearranged
tumors are related to some clinicopathologic features, such as
young age, never-smokers, and histology with a mucinous
cribriform pattern or signet ring cells, as shown in previous
reports [24,26]. However these characteristics were not perfectly
correlated with the presence of gene rearrangements. Given that
driver genetic alterations (EGFR mutation, KRAS mutation,
ROS1 rearrangement, and ALK rearrangement) were mutually
exclusive in both cohorts, driver mutation-negative cases are
highly recommended for further genetic testing. Specifically, the
combined incidence of ROS1 and ALK rearrangements increased
from 10% in all patients to 15.6% in patients with wild-type
EGFR and KRAS.
In conclusion, IHC is an effective screening tool for the
detection of ROS1-rearranged adenocarcinomas. ROS1 IHC is
highly sensitive, but less specific compared with ALK IHC in that
ROS1 is more frequently expressed in non-rearranged tumors.
ROS1 IHC-reactive tumors, especially when the tumor is stained
with moderate to strong intensity or a diffuse pattern, are
recommended to undergo FISH to confirm the gene rearrange-
ment.
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